米国の不眠症治療市場予測（～2021）：非薬理学的療法別（認知行動療法、催眠療法）、処方せん睡眠薬別（ベンゾジアゼピン、非ベンゾジアゼピン（ザレプロン）、オレキシン遮断薬,）、一般用治療別（抗ヒスタミン剤、メラトニン、ワレリアナ根））...市場調査レポートについてご紹介

TABLE OF CONTENTS

1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 KEY STAKEHOLDERS/INFLUENCERS
2. RESEARCH METHODOLOGY
2.1 MARKET SIZE ESTIMATION – NON-PHARMACOLOGICAL TREATMENTS MARKET
2.1.1 MARKET BREAKDOWN AND DATA TRIANGULATION
2.1.2 KEY DATA FROM SECONDARY SOURCES
2.1.3 KEY DATA FROM PRIMARY SOURCES
2.2 MARKET SIZE ESTIMATION – PHARMACOLOGICAL TREATMENTS MARKET
2.2.1 MARKET FORECAST MODEL
2.2.2 MARKET SIZE ESTIMATION
2.2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.2.4 KEY DATA FROM PRIMARY AND SECONDARY SOURCES
2.3 RESEARCH ASSUMPTIONS
3. EXECUTIVE SUMMARY
4. PREMIUM INSIGHTS
4.1 PHYSICIANS VIEWS ABOUT COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
4.2 AGE-WISE COMMONLY USED/PRESCRIBED TREATMENTS FOR EACH TYPE OF INSOMNIA
4.3 LIST OF ONGOING PHASE-III CLINICAL TRAILS FOR INSOMNIA
4.4 U.S. INSOMNIA MARKET: CONSUMER SELECTION CRITERIA

5. MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MARKET DRIVERS
5.2.1.3 GOVERNMENT SUPPORT TO CONTROL RISING INSOMNIA COST
5.2.1.4 OTC SLEEP AIDS TO DRIVE THE PHARMACOLOGICAL TREATMENT MARKET GROWTH
5.2.2 MARKET RESTRAINTS
5.2.2.1 EROSION IN BRANDED PRESCRIPTION SLEEP AID SALES DUE TO GROWING ADOPTION OF GENERICS
5.2.2.2 SIDE EFFECTS OF BENZODIAZEPINE AND NON-BENZODIAZEPINE DRUGS
5.2.2.3 NON PHARMACOLOGICAL THERAPIES TO RESTRICT THE GROWTH OF DRUGS MARKET
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 UNMET NEED FOR MORE EFFECTIVE AND SAFE DRUGS
5.2.3.2 PRESENCE OF LARGE INSOMNIA POPULATION POOL
6. NON-PHARMACOLOGICAL TREATMENT MARKET
6.1 INTRODUCTION
6.1.1 COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
6.1.2 HYPNOTHERAPY
6.1.3 OTHER ALTERNATIVE THERAPIES
6.2 THERAPY RECOMMENDATION, 2015 (%)
6.3 QUALITATIVE ASSESSMENT
7. PHARMACOLOGICAL TREATMENT MARKET
7.1 INTRODUCTION
7.2 U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TYPE
7.2.1 U.S.: PRESCRIPTION SLEEP AIDS MARKET SIZE FOR INSOMNIA
7.2.1.1 U.S.: PRESCRIPTION SLEEP AIDS MARKET SIZE FOR INSOMNIA,
BY TYPE
7.2.1.1.1 U.S.: NON- BENZODIAZEPINE SLEEP AIDS MARKET SIZE FOR INSOMNIA,
BY TYPE
7.2.2 U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE

8 . COMPETITIVE LANDSCAPE
8.1 KEY PLAYERS IN THE U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET
8.2 TOP AVAILABLE MOBILE APPLICATIONS FOR INSOMNIA
8.3 CORPORATE STRATEGIES FOLLOWED WITHIN U.S. INSOMNIA MARKET
8.4 COMPETITIVE SITUATIONS & TRENDS
8.4.1 PRODUCT LAUNCHES & APPROVALS
8.4.2 COLLABORATIONS, AGREEMENTS AND PARTNERSHIPS
8.4.3 ACQUISITIONS
9. COMPANY PROFILES
9.1 INTRODUCTION
9.2 MERCK & CO., INC.
9.3 EISAI CO., LTD.
9.4 MEDA CONSUMER HEALTHCARE, INC
9.5 TAKEDA PHARMACEUTICALS COMPANY LTD.
9.6 PFIZER INC.
9.7 SANOFI
9.8 VANDA PHARMACEUTICALS
9.9 PERNIX THERAPEUTICS
9.10 PURDUE PHARMACEUTICALS L.P.
10. APPENDIX
10.1 DISCUSSION GUIDE
10.2 RELATED REPORTS
10.3 RELATED REPORTS
10.4 KNOWLEDGESTORE SUBSCRIPTION PORTAL
10.5 MNM KNOWLEDGESTORE: SNAPSHOT
10.6 RT: REAL-TIME MARKET INTELLIGENCE
10.7 DISCLAIMER
10.8 AUTHOR DETAILS